• Skip to primary navigation
  • Skip to content
  • Skip to footer
CardioCell

CardioCell

Breakthrough Cardiovascular Technology

  • About Us
    • Overview
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Our Stem Cells
    • Manufacturing
    • Quality Control
    • Exclusive License
  • Clinical Trials
    • Overview
    • Chronic Heart Failure
    • Heart Failure in Patients With Left Ventricular Assist Devices
    • Acute Myocardial Infarction
  • News
    • Press Releases
    • Media Coverage
    • Publications
  • Events
  • LinkedIn

Stemedica plans to initiate Phase IIa 70-patient Alzheimer’s disease trial this year – executive

June 20, 2014

News


Jun 20, 2014

Stemedica plans to initiate Phase IIa 70-patient Alzheimer’s disease trial this year – executive

BioPharm

Another Stemedica subsidiary, CardioCell, has an exclusive, worldwide license for IV-administered allogeneic ischemia-tolerant mesenchymal stem cells (itMSCs). CardioCell manages trials in acute myocardial infarction, chronic heart failure and is exploring the use of the itMSCs in peripheral artery disease, according to the CardioCell website. SUBSCRIPTION REQUIRED TO READ FULL ARTICLE

Media Coverage

Reader Interactions

Footer

About Us

  • Overview
  • Board of Directors
  • Scientific Advisory Board

Technology

  • Our Stem Cells
  • Manufacturing
  • Quality Control
  • Exclusive License

Clinical Trials

  • Overview
  • Chronic Heart Failure
  • Heart Failure in Patients With Left Ventricular Assist Devices
  • Acute Myocardial Infarction
<section id="bpfwp_contact_card_widget-1" class="widget widget_bpfwp_contact_card_widget"><div class="widget-wrap"><h3 class="widgettitle widget-title">Contact</h3>
info@stemcardiocell.com
</div></section>

Copyright © 2023 · Business Pro Theme on Genesis Framework · WordPress · Log in